

Awake Proning in Patients with COVID-19 –a guidance from an international group of healthcare workers

Willemke Stilma

Teacher in nursing and researcher Intensive Care, Amsterdam University, Netherlands

Abstract

Vaccines are one of the major success stories of modern medicine. The development of vaccines progressed at a fairly slow rate until the last decade when new scientific discoveries and technologies led to innovative gene-based vaccines. Gene-based vaccines are a completely new type of vaccine that are faster and cheaper to produce than traditional vaccines. mRNA vaccines use a different approach that takes advantage of processes that are more efficient, cost-effective and safe. On the basis of these remarkable properties, mRNA vaccines quickly moved forward and within ten years were being used in some early clinical trials for infectious diseases and several types of cancer. The COVID-19 outbreak dramatically accelerated mRNA vaccines, moving them from development to authorized use in a record-setting ten months. In this review, we provide an overview of mRNA vaccine development and its application against the COVID-19 pandemic. As the first approved COVID vaccines, mRNA vaccines have been shown to be safe and mRNA technology will have a tremendous impact, not only on the pandemic, but also on the future treatment of many diseases.

Biography:

Willemke Stilma, lecturer in Nursing at the AUAS, is investigating whether cough machines offer a solution for patients in intensive care.

Citation : Willemke Stilma, Awake Proning in Patients with COVID-19 –a guidance from an international group of healthcare workers, Webinar on Covid Vaccines, April 29, 2021